Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 8/20 | 0.33 |
| ▸ | CNR2 | P34972 | 8/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3248875 | 0.84 | TACR1 (0.33) | TACR1GAA | |
| SCHEMBL3259020 | 0.84 | GAA (0.33) | KDM1AGAA | |
| SCHEMBL3258301 | 0.77 | GAA (0.38) | GAA | |
| SCHEMBL3255866 | 0.75 | TDP1 (0.35) | TACR1GAA | |
| SCHEMBL3254751 | 0.75 | TDP1 (0.35) | TACR1GAA | |
| SCHEMBL3253211 | 0.75 | TDP1 (0.35) | TACR1GAA | |
| SCHEMBL3255036 | 0.75 | GAA (0.34) | TACR1GAA | |
| SCHEMBL3253730 | 0.74 | GAA (0.34) | GAA | |
| SCHEMBL3254057 | 0.74 | TP53 (0.42) | KDM1AMAOBGAA | |
| SCHEMBL3258687 | 0.73 | GPBAR1 (0.39) | KDM1AMAOAMAOBTACR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741493-B2 | 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives; antiinflammatory agent, neurodegenerative diseases; inflammatory bowel disease, rheumatoid arthritis and diseases associated with central nervous system, such as Alzheimer's disease | AVENTIS PHARMACEUTICALS INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1651613-B1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMA INC (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7326792-B2 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1651613-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | Aventis Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014555-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | P2RX3, P2RX2, P2RX5 | KDM1A 2282/4885MAOA 1491/4885MAOB 946/4885 |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | P2RX3, P2RX2, P2RX5 | KDM1A 2282/4885MAOA 1491/4885MAOB 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.